Asarfi Hospital Ltd Q1 FY27 Results — Earnings Call Analysis

Published 24 Jun 2026 | Healthcare Services | Market Cap: ₹497 Cr

- Targeting revenue of INR 260 crores for FY27, up from INR 173.5 crores in FY26. - Asarfi Hospital targets revenue growth to INR 260 crores in FY27, with confidence in achieving this through bed expansions, increased patient flow, and service ramp-up.

From Asarfi Hospital Ltd's Q4 FY26 earnings-call transcript · updated 24 Jun 2026.

Price

212

Market Cap

₹497 Cr

P/E Ratio

29.6

Revenue Rank

Rank 2

Margin Rank

Rank 3

How does Asarfi Hospital Ltd rank in Healthcare Services?

Compare Asarfi Hospital Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 2Margin: Rank 3
View Healthcare Services leaderboard →

Asarfi Hospital Ltd — Quarterly revenue & net profit

Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹45 Cr, net profit ₹4 Cr.

Full financials →

📊 Revenue & Sales Performance

Rank 2
  • Targeting revenue of INR 260 crores for FY27, up from INR 173.5 crores in FY26.
  • Aim to scale overall bed capacity to over 500 beds by 2028 (from current 350 beds).
  • Cancer hospital capacity to increase from 65 beds to 150 beds, with significant revenue growth expected from this segment.
  • Revenue growth driven by bed expansion, occupancy ramp-up, ARPOB (Average Revenue Per Occupied Bed) improvement, transplant services, and management contracts.
  • Expect organic and inorganic growth, including hospital acquisitions planned in FY27.
  • Bone marrow transplant facility to start contributing revenue from FY28.
  • Long-term plan targets INR 400 crores revenue and EBITDA margin of 23-25%.
  • PAT growth expected to be aligned with revenue and EBITDA growth, with a focus on cost management and improved case mix.
  • Confident about sustaining momentum and 50% CAGR growth over next 4-5 years.

📈 Profitability & Margins

Rank 3
  • Asarfi Hospital targets revenue growth to INR 260 crores in FY27, with confidence in achieving this through bed expansions, increased patient flow, and service ramp-up.
  • The company aims to scale bed capacity to over 500 beds by 2028 and generate around INR 400 crores in revenue.
  • EBITDA margin is expected to improve from 20% in FY26 to 22-25% in FY27, with a focus on case mix optimization and cost management.
  • PAT margin guidance is 13-15% for FY27, with efforts to maintain PAT growth consistent with revenue growth.
  • Expansion drivers include cancer hospital growth (increasing from 65 to 150 beds), bone marrow transplant facility commencement (FY28 contribution), and inorganic growth via hospital acquisitions.
  • Management intends to achieve 50% CAGR growth over the next 4-5 years, maintaining strong profitability and operational discipline.
  • Internal accruals are expected to fund growth, with limited reliance on debt unless major capex opportunities arise.

🏗️ Capital Expenditure Plans

Yes
  • Healthcare Management Research Institute under construction with expected capex of INR 8 to 10 crores in the coming fiscal year.
  • Additional capex of INR 2 to 3 crores planned to unlock current capacity and expand super specialty and oncology beds — total FY27 capex expected to be under INR 15 crores.
  • Bed expansion plan to increase cancer hospital beds from 65 to 150, with relatively low capex of INR 2 to 3 crores due to existing infrastructure.
  • Inorganic growth through hospital acquisition is underway, with technical issues being resolved and materialization expected within the financial year.
  • Potential strategic management contracts and partnerships in nearby regions are in exploration as part of growth strategy.
  • Main board migration process initiated after July eligibility.
  • Future expansions and hospital additions planned, but model still under development considering government cashless scheme constraints.

💰 Fundraising & Capital Structure

Yes
  • Asarfi Hospital Limited has not currently decided to raise debt for further growth.
  • Growth is planned to be managed through internal accruals as of now.
  • However, the management remains open to taking debt if a major capital expenditure or opportunity arises.
  • In the recent call, it was mentioned that if any significant funding need arises, the company will inform stakeholders accordingly.
  • Regarding equity fundraising, no explicit mention of new equity issuance or fundraising was made during the call.
  • The company is focused on organic and inorganic growth, including potential acquisitions, which might require funding.
  • Cash holdings are currently between INR 8 crores to INR 10 crores, which provide some liquidity.
  • Overall, no immediate plans for fundraising but flexibility to consider debt depending on opportunities.

📋 Order Book & Pipeline

No information
The transcript provided does not mention any details regarding current or expected order book or pending orders for Asarfi Hospital Limited. The discussion focuses primarily on: - Operational performance, bed capacity expansion - Revenue and EBITDA guidance - Government scheme reimbursements and delays - Capital expenditure plans and acquisitions - Growth outlook and strategic initiatives No specific information on order book or pending orders was disclosed in the Q4 & FY26 earnings conference call transcript.

Key Metrics

Revenue

Rank 2

Margin

Rank 3

Capex

Yes

Fundraise

Yes

Order Book

No information

Frequently Asked Questions

What were Asarfi Hospital Ltd Q1 FY27 results?

- Targeting revenue of INR 260 crores for FY27, up from INR 173.5 crores in FY26. - Asarfi Hospital targets revenue growth to INR 260 crores in FY27, with confidence in achieving this through bed expansions, increased patient flow, and service ramp-up.

What is Asarfi Hospital Ltd share price analysis?

Asarfi Hospital Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 29.6 with a market cap of ₹497. Investors should review the full earnings analysis for detailed insights.

Is Asarfi Hospital Ltd planning capital expenditure?

- Healthcare Management Research Institute under construction with expected capex of INR 8 to 10 crores in the coming fiscal year.

Keep Asarfi Hospital Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

What Asarfi Hospital's management said in earlier quarters

Others in Healthcare Services this season

  • Park Medi World (Q4 FY26)

    Total planned capex for the next two years is around INR 500 crores. Key concall takeaways from Park Medi World's Q4 FY26 earnings call — and how it ranks…

  • Vimta Labs Ltd (Q4 FY26)

    . Key concall takeaways from Vimta Labs Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.

  • Vijaya Diagnost. (Q4 FY26)

    Hyderabad to sustain double-digit growth (~20%) in near term, with additional spokes opening and market share gains. Key concall takeaways from Vijaya…

  • Thyrocare Tech. (Q4 FY26)

    Q4 FY26 test volume growth surged to ~29%, driven by competitive pricing in biochemistry tests. Key concall takeaways from Thyrocare Technologies Ltd's Q4 FY26…